Christopher Griffith, MD
Gastroenterology · Southaven, MSNPI 1588735617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 39.6% of the total. Reporting peaked in 2022 at $1,860 and has fallen 51.2% since, to $908 in 2025.
Across 404 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$783
- Takeda Pharmaceuticals U.S.A., Inc.$480
- Pfizer$464
- Nestle Healthcare Nutrition Inc.$228
- Johnson & Johnson$192
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,14899%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 173 | $2,454 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 57 | $783 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $480 |
| Pfizer | 23 | $464 |
| Nestle Healthcare Nutrition Inc. | 12 | $228 |
| Johnson & Johnson | 13 | $192 |
| Bristol Myers Squibb | 13 | $180 |
| QOL Medical, LLC | 9 | $159 |
| Sanofi | 5 | $147 |
| Ardelyx, Inc. | 5 | $116 |
| Lilly USA, LLC | 7 | $114 |
| Ferring Pharmaceuticals Inc. | 7 | $113 |
| Aimmune Therapeutics, Inc. | 6 | $108 |
| Merck | 6 | $88 |
| Intercept Pharmaceuticals, Inc. | 6 | $86 |
| Daiichi Sankyo Inc. | 4 | $66 |
| UCB, Inc. | 4 | $52 |
| Gilead | 4 | $51 |
| Celltrion USA Inc. | 2 | $46 |
| Madrigal Pharmaceuticals | 2 | $41 |
| Evoke Pharma, Inc. | 2 | $28 |
| Micro-tech Endoscopy USA, Inc. | 1 | $28 |
| Redhill Biopharma Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Boston Scientific | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Enterra Medical, Inc. | 1 | $18 |
| Ambu Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Cook Medical LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,193 in reported general payments places this provider in the 60th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 127 | $98,311 |
| XifaxanRifaximin | 16 | $41,775 |
| CreonLipase/Protease/Amylase | 19 | $36,138 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 145 | $24,380 |
| Mesalamine | 19 | $5,588 |
| Balsalazide Disodium | 30 | $4,221 |
| Omeprazole | 350 | $3,771 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 22 | $3,041 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 45 | $3,027 |
| Pantoprazole Sodium | 235 | $2,537 |
| Lubiprostone | 13 | $2,449 |
| Ursodiol | 14 | $2,258 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 16 | $1,952 |
| Colestipol Hcl | 32 | $1,838 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 98 | $1,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,454 | $134,449146 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $783 | $44,81638 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $113 | $24,380145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Southaven
- Nabeel KhanSouthaven$23K
- Ulric DuncanSouthaven$22K
- Eric OrmsethSouthaven$9K
- Geza RemakSouthaven$8K
- Sufiyan ChaudhrySouthaven$5K
- Wassem JuakiemBiloxi$519K
- Reed HoganFlowood$216K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.